Drug intelligence / Profile preview

nystatin + didanosine

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

**Nystatin + didanosine** is a fixed-dose combination of two pharmaceuticals: **nystatin**, an antifungal polyene macrolide, and **didanosine**, a nucleoside reverse transcriptase inhibitor (NRTI). - **Nystatin** binds to ergosterol in the fungal cell membrane, forming pores that lead to leakage of cellular contents, and is primarily used for the treatment of Candida infections. - **Didanosine** is an antiretroviral drug that inhibits HIV-1 reverse transcriptase by acting as a chain terminator during viral DNA synthesis. This combination may be co-formulated to exploit nystatin’s antiviral/antifungal prophylactic effect in immunocompromised patients, such as those with HIV/AIDS treated with didanosine, to prevent oral or gastrointestinal candidiasis. However, no evidence in the provided search results indicates the existence of a unique approved product under this exact combination name, though both medicines are used in HIV/AIDS care.

02

Targets

Human immunodeficiency virus type 1 reverse transcriptaseErgosterol

Beyond the preview

Go deeper on nystatin + didanosine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nystatin + didanosine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call